Library — CHDR

Search

Filter

Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating Scale.

Otto ME, Bergmann KR, de Kam ML, Recourt K, Jacobs GE, van Esdonk MJ

CPT: pharmacometrics & systems pharmacology, 2023 Aug

View publication
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool.

Kwee CM, van Gerven JM, Bongaerts FL, Cath DC, Jacobs G, Baas JM, Groenink L

Journal of psychopharmacology (Oxford, England), 2022 Dec; 36(12):1299-1314

View publication
Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double-blind placebo-controlled cross-over study.

Ruijs TQ, Koopmans IW, de Kam ML, Tannemaat MR, Groeneveld GJ, Heuberger JAAC

Clinical and translational science, 2022 Dec; 15(12):2971-2981

View publication
Monitoring of Ex Vivo Cyclosporin a Activity in Healthy Volunteers Using T Cell Function Assays in Relation to Whole Blood and Cellular Pharmacokinetics.

In 't Veld AE, Jansen MAA, Huisman BW, Schoonakker M, de Kam ML, Moes DJAR, van Poelgeest MIE, Burggraaf J, Moerland M

Pharmaceutics, 2022 Sep

View publication
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease.

Baakman AC, Gavan C, van Doeselaar L, de Kam M, Broekhuizen K, Bajenaru O, Camps L, Swart EL, Kalisvaart K, Schoonenboom N, Lemstra E, Scheltens P, Cohen A, van Gerven J, Groeneveld GJ

British journal of clinical pharmacology, 2022 Jun; 88(6):2814-2829

View publication
Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers.

Dijkstra FM, Zuiker RGJA, Siebenga PS, Leigh-Pemberton RA, Sun L, Manthis JD, de Kam ML, Lin R, von Moltke LL, Rezendes D, van Gerven JMA

British journal of clinical pharmacology, 2022 Jun; 88(6):2909-2925

View publication
A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.

Thijssen E, den Heijer J, Puibert D, Moss L, Lei M, Hasegawa D, Keum K, Mochel K, Ezzeldin Sharaf M, Alfredson T, Zeng W, van Brummelen E, Naranda T, Groeneveld GJ

Movement disorders : official journal of the Movement Disorder Society, 2022 Apr; 37(4):790-798

View publication
A phase I, randomized, double-blind, placebo-controlled, single- and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX-128, a highly selective Na 1.8 inhibitor, in healthy adults.

Hijma HJ, van Brummelen EMJ, Siebenga PS, Groeneveld GJ

Clinical and translational science, 2022 Apr; 15(4):981-993

View publication
Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.

Wind SS, Jansen MAA, Rijsbergen M, van Esdonk MJ, Ziagkos D, Cheng WC, Niemeyer-van der Kolk T, Korsten J, Gruszka A, Schmitz-Rohmer D, Bonnel D, Legouffe R, Barré F, Bekkenk MW, de Haas ERM, Quint KD, Rolli M, Streefkerk HJ, Burggraaf J, Vermeer MH, Rissmann R

Cancers, 2022 Mar

View publication

«
1
2
3
4
5
6
7
»